|
|
|
Volumn 6, Issue 3, 2008, Pages 174-175
|
|
K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
ERLOTINIB;
FLUOROPYRIMIDINE DERIVATIVE;
GEFITINIB;
GEMCITABINE;
IRINOTECAN;
K RAS PROTEIN;
MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;
OXALIPLATIN;
PANITUMUMAB;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CODON;
COLORECTAL CANCER;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG SENSITIVITY;
FOOD AND DRUG ADMINISTRATION;
GENE OVEREXPRESSION;
HUMAN;
INJECTION SITE REACTION;
METASTASIS;
MONOTHERAPY;
SCREENING;
SKIN TOXICITY;
SOMATIC MUTATION;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS AS TOPIC;
COLORECTAL NEOPLASMS;
DRUG RESISTANCE, NEOPLASM;
GENES, RAS;
HUMANS;
IMMUNOLOGIC FACTORS;
MUTATION;
NEOPLASM METASTASIS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 42049120917
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (8)
|
|
References (3)
|
